1. Generics Bulletin
  2. >>Business
  3. >>Deals

Deals Abound At Advanz

Company Has Closed Or Signed Several Agreements Since Early September

 
• By Chloe Kent

Advanz has acquired exclusive rights to register and commercialize a Phase III candidate from Dimerix in multiple territories, alongside agreements with Kyowa Kirin, Bayer and GP Pharm.

Mixed media image showing two men shaking hands superimposed over a cityscape
Advanz has signed or completed four major deals over the last few weeks • Source: Shutterstock

Recent weeks have seen Advanz Pharma make a number of portfolio-diversifying deals, including licensing and supply agreements and product acquisitions. Most notably, the company has acquired exclusive rights to register and commercialize Dimerix’s Phase III drug candidate DMX-200.

More from Deals

More from Business

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Speranza Starts Generics Offshoot In Response To Wider US Pharma Manufacturing Drive

 
• By Adam Zamecnik

Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.